Apollo Hospitals posted strong financial results for the quarter.

1. **Business Performance:** Consolidated revenue grew 17% YoY to ₹6,477.4 Cr.

EBITDA increased 27% to ₹965.3 Cr, and PAT surged 35% to ₹502.3 Cr.

Healthcare Services revenue rose 14% to ₹3,183.2 Cr, with EBITDA up 18%. Diagnostics & Retail Health (AHLL) revenue jumped 20% to ₹466.8 Cr, with EBITDA growing 39%, driven by diagnostics.

Digital Health & Pharmacy Distribution (Apollo HealthCo) revenue increased 20% to ₹2,827.4 Cr, and PAT soared 170% to ₹86.6 Cr, achieving its lowest digital cash loss of ₹29.2 Cr.

2. **Growth Drivers or Strategy:** The company plans to add ~3,600 new census beds over the next five years, investing ~₹8,200 Cr.

HealthCo boosted diagnostic GMV by expanding to 18 new cities and focusing on omni-channel growth.

3. **Recent Developments:** Notable clinical advancements include gene therapy for Spinal Muscular Atrophy and a new multi-robot surgery center.

HealthCo expanded its insurance business and launched a collaboration with TOI for Ask Apollo.

4. **Key Financial Metrics:** Revenue growth 17% YoY, EBITDA growth 27% YoY, PAT growth 35% YoY.

5. **Management Commentary / Outlook:** Apollo anticipates an annualized revenue run rate of ₹25,000 Cr by Q4 FY27 with a 7% EBITDA margin.

The composite scheme for Apollo HealthCo to be an Indian Owned and Controlled Company (IOCC) and list on exchanges is targeted for Q4 FY27.